Cytochrome P450 in Pharmacogenetics: An Update

Show full item record



Tornio , A & Backman , J T 2018 , ' Cytochrome P450 in Pharmacogenetics: An Update ' , Advances in Pharmacology , vol. 83 , pp. 3-32 .

Title: Cytochrome P450 in Pharmacogenetics: An Update
Author: Tornio, A.; Backman, J.T.
Contributor organization: Department of Clinical Pharmacology
Staff Services
Janne Backman / Principal Investigator
University Management
Doctoral Programme in Drug Research
Date: 2018
Language: eng
Number of pages: 30
Belongs to series: Advances in Pharmacology
ISSN: 1054-3589
Abstract: Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6, CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far the evidence regarding their clinical implications is not as conclusive. In this review, we provide an up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes, focusing on clinically significant examples. © 2018 Elsevier Inc.
Description: cited By 1
Subject: 317 Pharmacy
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
AdvPhTornioBackman_FinalDraft.pdf 436.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record